ENESDENewsletter →
Shotlee
Get the app
📖Полный гид✅Обновлено 2026🔬Доказательная база

Гид по Orforglipron

Таблетка ГПП-1 без инъекций и ограничений по еде

Orforglipron — это оральный непептидный агонист ГПП-1 от Eli Lilly. Не требует уколов и соблюдения окна голодания перед приемом. Исследование ATTAIN показало 14.7% потери веса за 36 недель.

Загрузите вApp Store
Доступно вGoogle Play
ATTAIN-1 (72 weeks)
Up to 27.3 lbs
In the first obesity Phase 3 readout, Lilly reported up to 27.3 lbs average weight reduction at 72 weeks in adults without type 2 diabetes, supporting
HbA1c Reduction
Up to 2.2%
Regulatory Window
2025-2026
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
OrforglipronB12
ORFORGLIPRON
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Orforglipron
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
OrforglipronRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
Dashboard
Your complete health overview in one place
🔥
14-day streak
Logged 18 of 18 scheduled shots
Next Shot Reminder
⌄
ACTIVE MEDICATIONS
OrforglipronB12
ORFORGLIPRON
🔥 14
2
days away
Thursday · 7.5mg
⌄
Medication Supply
Orforglipron
6.2 / 10 mg · Vial
~42 days left · Mar 15
B12
4.4 / 5 ml · Vial
~88 days left · May 8
Retatrutide
1.2 / 5 mg · Vial
~6 days left · refill soon
Medication Levels
7 Days2 Weeks1 Month90 Days
CURRENT LEVEL
5.42mg
Mar 6
Today
ACTIVE MEDICATIONS
OrforglipronRetatrutide
0mg2.7mg5.4mg
18
Total Injections
💉 All time
122/78
Average BP
🩺 mmHg
8.4
Avg Mood
😊 /10
Health Chart
1mAll
218.6lb
↓ 8.4 lb · 3.7%
WeightInjectionsBPMood
2282222162102277.5mg7.5mg4mg10mg218
Feb 6Feb 14Feb 22Mar 2Today
Photos
12 photos · 2w streak
Week 1
Week 7
Today
Scheduled Reminders
Weight
Due today
Mood
Done
Blood Pressure
Tomorrow
Body Measurements
In 3 days
01BACKGROUND

Что такое Orforglipron?

Orforglipron (LY3502970) — это экспериментальный оральный агонист рецепторов ГПП-1 от компании Eli Lilly. В отличие от других препаратов ГПП-1, это малая молекула (не пептид), что позволяет ей выживать в пищеварительной системе без специальных технологий защиты.

Почему это важно: текущие оральные ГПП-1 (например, Rybelsus) требуют строгого голодания, так как пептид семаглутид очень хрупок. Структура Orforglipron более устойчива, что позволяет принимать его в любое время, даже с едой.

Применение: одна таблетка в день, независимо от приема пищи. Никаких инъекций и сложных правил.

02DEEP DIVE

Ключевые преимущества механизма

Key advantage: Rybelsus's strict requirements cause poor adherence. Orforglipron's flexibility could dramatically improve real-world effectiveness.

03MECHANICS

Результаты клинических испытаний

1
Activates GLP-1 receptors
2
Reduces appetite and cravings
3
Slows gastric emptying
4
Improves blood sugar control
5
Similar efficacy to injectable GLP-1s
6
Survives stomach acid intact
7
Absorbs well with food present
8
Consistent blood levels
9
No complex formulation needed
10
Easier manufacturing at scale
04KEY NUMBERS

Ожидаемые дозировки

📈
ATTAIN-1 (72 weeks)
0.0lbs
In the first obesity Phase 3 readout, Lilly reported up to 27.3 lbs average weight reduction at 72 weeks in adults without type 2 diabetes, supporting
💪
HbA1c Reduction
0.0%
🏆
Regulatory Window
0-2026
05WHAT TO TRACK

Who Will Benefit Most?

01
🔬
Ideal Candidates
Needle-phobic patients. Those who can't follow Rybelsus restrictions. People with irregular schedules. Those who prefer pills over injections. Patients starting GLP-1 therapy
02
🔬
Consider Alternatives If
You need maximum weight loss (injectables may be stronger). You prefer weekly dosing over daily. You respond well to current GLP-1s. You want dual/triple agonist effects
06DOSING

Expected Dosing

Week 1
3mg daily
Week 2
6mg daily
Week 3-4
12-24mg daily
Maintenance
36-45mg daily
07WHAT TO TRACK

Side Effects

01
🔬
Common (Similar to all GLP-1s)
Nausea (most common). Vomiting. Diarrhea. Constipation. Decreased appetite
02
📊
Trial Observations
Side effects similar to injectable GLP-1s. GI effects typically mild-moderate. Improved with slower dose escalation. No unexpected safety signals. Well-tolerated overall
08TIMELINE

Development Timeline

2023:
Phase 2 results published (obesity and T2D)
2025:
Positive Phase 3 obesity and diabetes readouts reported (ATTAIN / ACHIEVE)
Late 2025-2026:
Regulatory submissions announced/planned by Lilly for obesity and diabetes progr — Regulatory submissions announced/planned by Lilly for obesity and diabetes programs
Current status:
As of March 6, 2026, orforglipron remains investigational and not FDA approved
09WHAT TO TRACK

Why This Changes Everything

01
🔬
Easier Manufacturing
Small molecules are cheaper and faster to produce than peptides, potentially reducing shortages.
02
💰
Potentially Lower Cost
Simpler production could mean lower prices compared to injectable biologics.
03
🔬
Global Access
No cold chain required for pills. Easier distribution worldwide, including developing markets.
10WHAT TO TRACK

Vital Protocol FAQs

01
🔬
Is Orforglipron as effective as Ozempic?
Orforglipron has now reported meaningful Phase 3 efficacy, but exact cross-drug comparisons depend on dose and study population. Injectable semaglutide and tirzepatide still have broader approved evid
02
🔬
Can I really take it with food?
Yes. Unlike Rybelsus, Orforglipron's small molecule structure allows absorption regardless of food intake. You can take it with breakfast, lunch, dinner, or any meal—or without food entirely.
03
🔬
Why daily instead of weekly?
Small molecules are cleared from the body faster than peptides. While this means daily dosing, the trade-off is flexibility and convenience. For many patients, a daily pill with no restrictions beats
04
🔬
Will there be a weekly oral GLP-1?
Potentially. Eli Lilly and other companies are exploring longer-acting oral formulations. However, Orforglipron's daily dosing with no restrictions may be preferable to a weekly dose with strict requi
11FAQ

Вопросы по руководству

Это первая в мире таблетка ГПП-1 на основе малой молекулы, которую можно принимать без ограничений по еде и без уколов.

Да, Shotlee поддерживает логирование доз Orforglipron, мониторинг веса и побочных эффектов.

Free · Always

Отслеживайте протокол Orforglipron в Shotlee

Бесплатный журнал дозировок, трекинг побочных эффектов и мониторинг показателей здоровья для вашего протокола.

Загрузите вApp Store
Доступно вGoogle Play

📚References & sources

🔗Keep exploring

Все руководства
→
Трекеры
→
Start tracking